Tune into this episode of BiotechTV at #ASGCT25, where Brad Loncar and Eric Kelsic talk more in depth about the science behind the CNS, eye, and neuromuscular capsids we launched this week, as well as the Dyno Frontiers Program and upcoming GATC conference, and how they’re designed to help end users access better therapies by tackling delivery challenges at scale.
𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟓: Dyno Therapeutics CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions. He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body. Plus, the company's new 'Frontiers Program' and a Genetic Agency Technology Conference coming up in November. Full video: https://lnkd.in/g-RCrH2V BiotechTV's coverage of the 2025 ASGCT Annual Meeting is brought to you by NewBiologix. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills
